Prognostic significance of the c-erbB-2 oncogene product in childhood medulloblastoma.
about
Cellular immunotherapy for pediatric solid tumorsMedulloblastoma: tumorigenesis, current clinical paradigm, and efforts to improve risk stratificationCIC, a gene involved in cerebellar development and ErbB signaling, is significantly expressed in medulloblastomas.Integrated genomics identifies five medulloblastoma subtypes with distinct genetic profiles, pathway signatures and clinicopathological features.Immunotherapy for osteosarcoma: genetic modification of T cells overcomes low levels of tumor antigen expression.Molecular heterogeneity in medulloblastoma with implications for differing tumor biology.Exogenous HGF Bypasses the Effects of ErbB Inhibition on Tumor Cell Viability in Medulloblastoma Cell LinesDetermination of HER-2/neu overexpression and clinical predictors of survival in a cohort of 347 patients with primary malignant brain tumors.Prognosis-related molecular markers in pediatric central nervous system tumors.Recent advances in embryonal tumours of the central nervous system.Molecular biology of medulloblastoma: will it ever make a difference to clinical management?Emerging treatments and gene expression profiling in high-risk medulloblastoma.Pediatric CNS tumors: current treatment and future directions.Aggressive infantile embryonal tumors.Tyrosine kinase inhibitors in pediatric malignancies.The rationale for targeted therapies in medulloblastoma.Cytogenetic prognostication within medulloblastoma subgroups.Treatment of posterior fossa tumors in children.Targeting brain cancer: advances in the molecular pathology of malignant glioma and medulloblastoma.Pediatric neuro-oncology: current status and future directions.C-erbB2/HER2 in human gliomas, medulloblastomas, and meningiomas: a minireview.Bone marrow-derived dendritic cells pulsed with a tumor-specific peptide elicit effective anti-tumor immunity against intracranial neoplasms.HER2-specific T cells target primary glioblastoma stem cells and induce regression of autologous experimental tumorsMedulloblastoma sensitivity to 17-allylamino-17-demethoxygeldanamycin requires MEK/ERKM.Impact of molecular biology studies on the understanding of brain tumors in childhood.Immunohistochemical expression of markers Ki-67, neun, synaptophysin, p53 and HER2 in medulloblastoma and its correlation with clinicopathological parameters.Recurrence in medulloblastoma - influence of clinical, histological and immunohistochemical factors.Durable regression of Medulloblastoma after regional and intravenous delivery of anti-HER2 chimeric antigen receptor T cells.Do medulloblastoma tumors meet the Food and Drug Administration criteria for anti-erbB2 therapy with trastuzumab?
P2860
Q27014912-2068BC57-E39E-4CA6-9484-6F16D5153B44Q28299667-FB92892A-CFE2-449F-893A-E715C666B550Q33217989-1FCD63CA-EE63-4FF2-BC71-EEB2E4835F97Q33366431-037B215A-0C96-4638-A6A9-F96256D24FC0Q33713042-DA32D231-D2D5-4B59-8945-A52E8C3AA577Q33779968-E20A42D4-815D-4F3B-B5A1-F56281E87398Q35818728-E863822D-18CB-4B8D-82C4-74E7A56CEAAEQ35964401-F63D61F9-0A5C-4F57-8847-4D2B7EEE2B5EQ35996275-B2B65A6C-55DF-4969-8F8C-D19FDEE0CC11Q36025403-4C4D43A3-DF34-45BD-A8E8-BEB0F26C8E4EQ36273001-4F22FC2B-5685-4D3F-A12A-3D0D04FAD6EEQ36779651-109B7F82-9E29-4311-B83C-F023C07B6358Q36902043-1126B78B-9119-4340-A482-7CFED11E9914Q36907570-D8DAB137-3489-4F2B-A820-F72AFEBE50EEQ36977823-2C274CD5-11AB-4320-9E50-CF6F99C85098Q37409736-E974B084-4D5E-4585-A10F-468538ABEA9BQ37627692-8C52A034-DF28-4163-B932-417784F4E430Q37724213-5F27FEC8-D3DA-4E9E-9400-A73A3BE465FCQ37736255-1FAD91E2-62F8-47B8-AE96-F29684E307A0Q38035070-AE504F92-65D2-45C8-811D-72A864B0772AQ38120594-FF1FE3BD-A6F8-42E7-8B2C-707FFABDB9CDQ41005830-BE752E26-47F2-404D-8C75-8F095375FA9DQ41783221-29AA2269-040E-418E-A9CF-C29D887B9E5FQ42440167-6296D545-EEA1-47FA-9323-7E6A49355DCFQ48716816-30B73467-A008-4C7B-B9DE-8BAE0C551EACQ49056530-B0D1A09C-9883-49D5-8413-7BDB367B9482Q51771306-A76C3ACF-C7B8-429F-AFFA-BABDF6B5A893Q52715479-9E520C77-C3AD-4AB0-AD44-021FD28A9E2BQ55470122-2DD082BD-4B53-48F1-A3FC-FC680BCE59C6
P2860
Prognostic significance of the c-erbB-2 oncogene product in childhood medulloblastoma.
description
1995 nî lūn-bûn
@nan
1995年の論文
@ja
1995年論文
@yue
1995年論文
@zh-hant
1995年論文
@zh-hk
1995年論文
@zh-mo
1995年論文
@zh-tw
1995年论文
@wuu
1995年论文
@zh
1995年论文
@zh-cn
name
Prognostic significance of the c-erbB-2 oncogene product in childhood medulloblastoma.
@ast
Prognostic significance of the c-erbB-2 oncogene product in childhood medulloblastoma.
@en
type
label
Prognostic significance of the c-erbB-2 oncogene product in childhood medulloblastoma.
@ast
Prognostic significance of the c-erbB-2 oncogene product in childhood medulloblastoma.
@en
prefLabel
Prognostic significance of the c-erbB-2 oncogene product in childhood medulloblastoma.
@ast
Prognostic significance of the c-erbB-2 oncogene product in childhood medulloblastoma.
@en
P2093
P2860
P356
P1476
Prognostic significance of the c-erbB-2 oncogene product in childhood medulloblastoma.
@en
P2093
P2860
P2888
P304
P356
10.1038/BJC.1995.96
P407
P577
1995-03-01T00:00:00Z